» Articles » PMID: 12954047

Synthesis and Activity of New Aryl- and Heteroaryl-substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain

Abstract

Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TbetaR-I receptor kinase domain.

Citing Articles

Chemoproteomic Profiling of for Characterization of Anti-fungal Kinase Inhibitors.

Shirley D, Nandakumar M, Cabrera A, Yiu B, Puumala E, Liu Z bioRxiv. 2025; .

PMID: 39829896 PMC: 11741263. DOI: 10.1101/2025.01.10.632200.


Hydrogen sulfide donor NaHS inhibits formaldehyde-induced epithelial-mesenchymal transition in human lung epithelial cells via activating TGF-β1/Smad2/3 and MAPKs signaling pathways.

Wang H, Jia M, Chang Y, Ling X, Qi W, Chen H Curr Res Toxicol. 2024; 7:100199.

PMID: 39524036 PMC: 11550156. DOI: 10.1016/j.crtox.2024.100199.


Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy.

Wen J, Liu D, Zhu H, Shu K J Neuroinflammation. 2024; 21(1):226.

PMID: 39285276 PMC: 11406851. DOI: 10.1186/s12974-024-03222-4.


Systematic computational strategies for identifying protein targets and lead discovery.

Kataria A, Srivastava A, Singh D, Haque S, Han I, Yadav D RSC Med Chem. 2024; 15(7):2254-2269.

PMID: 39026640 PMC: 11253860. DOI: 10.1039/d4md00223g.


Structure-Guide Design and Optimization of Potential Druglikeness Inhibitors for TGFβRI with the Pyrrolopyrimidine Scaffold.

Meng D, Xie J, Li Y, Li R, Zhou H, Deng P Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297376 PMC: 9653795. DOI: 10.3390/ph15101264.